The effectiveness of sucralfate against stricture formation in experimental corrosive esophageal burns.
OBJECTIVE
In this study, the effectiveness of sucralfate against stricture formation in experimental corrosive esophageal burn is reported.


METHODS
Sixty-four Swiss albino adult male rats were divided into three groups, group A (control; n, 7), group B (esophageal burn induced but not treated; n, 25), and group C (esophageal burn induced and treated with sucralfate, n, 32). Groups B and C were further subdivided into subgroups for evaluation on days 2, 7, and 28. A standard esophageal burn was performed by the method of Gehanno, using 50% NaOH. Oral sucralfate treatment was given to group C at a dosage of 50 mg/100 g twice daily. The rats were then killed after 2, 7, or 28 days. Levels of tissue hydroxyproline were measured in excised abdominal esophageal segments, and a histopathological evaluation was performed with hematoxylin-eosin and Masson's trichrome staining.


RESULTS
The tissue hydroxyproline levels were significantly lower in group C than in group B (P = 0.017). There was a significant difference in the stenosis index between groups B and C (P = 0.016). When compared with group B, the collagen deposition in the submucosa and tunica muscularis was significantly lower in group C (P = 0.02).


CONCLUSIONS
Sucralfate has an inhibitory effect on stricture formation in experimental corrosive burns and can be used in the treatment of corrosive esophageal burns to enhance mucosal healing and suppress stricture formation.
Temir
Z Günyüz
ZG
Department of Pediatric Surgery, Dr. Behçet Uz Children's Hospital, 35210 IIzmir, Turkey.
Karkiner
Aytaç
A
Karaca
Irfan
I
Ortaç
Ragip
R
Ozdamar
Aykut
A
D000818:Animals; D002057:Burns, Chemical / Q000150:complications* / Q000209:etiology / Q000378:metabolism; D002424:Caustics / Q000009:adverse effects; D004940:Esophageal Stenosis / Q000209:etiology / Q000517:prevention & control*; D004947:Esophagus / Q000293:injuries*; D006909:Hydroxyproline / Q000032:analysis; D008297:Male; D051379:Mice; D023421:Models, Animal; D020011:Protective Agents / Q000627:therapeutic use*; D051381:Rats; D012972:Sodium Hydroxide / Q000009:adverse effects; D013392:Sucralfate / Q000627:therapeutic use*; D016896:Treatment Outcome; D014945:Wound Healing / Q000502:physiology
D002424:Caustics; D020011:Protective Agents; D013392:Sucralfate; D012972:Sodium Hydroxide; D006909:Hydroxyproline